Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human MAP3K11 Anticorps:
anti-Mouse (Murine) MAP3K11 Anticorps:
anti-Rat (Rattus) MAP3K11 Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Polyclonal MAP3K11 Primary Antibody pour WB - ABIN4334888
Chien, Lin, Wang, Lee, Chen, Fong, Shih: Acacetin inhibits the invasion and migration of human non-small cell lung cancer A549 cells by suppressing the p38α MAPK signaling pathway. dans Molecular and cellular biochemistry 2011
These results suggest that in the early response to stressful stimuli, MLK4beta-MLK3 binding is important for regulating MLK3 activity and MAPK (Montrer MAPK1 Anticorps) signalling, and after prolonged periods of stress exposure, MLK4beta and MLK3 proteins decline via CHIP-dependent degradation.
In summary, this investigation identifies an EGFR (Montrer EGFR Anticorps)-DOCK180 (Montrer DOCK1 Anticorps)-RAC1 (Montrer RAC1 Anticorps)-MLK3-JNK (Montrer MAPK8 Anticorps) signaling axis that drives glioblastoma cell migration and dissemination.IMPLICATIONS: On the basis of these findings, MLK3 emerges as a potential therapeutic target for the treatment of glioblastoma
chronic hypoxia can reduce MLK3 expression in a posttranscriptional regulatory manner.
In lipotoxic hepatocytes, MLK3 activates a MAPK (Montrer MAPK1 Anticorps) signaling cascade, resulting in the activating phosphorylation of STAT1 (Montrer STAT1 Anticorps), and CXCL10 (Montrer CXCL10 Anticorps) transcriptional upregulation.
Data indicate that BTG2 (Montrer BTG2 Anticorps), MAP3K11, RPS6KA1 (Montrer RPS6KA1 Anticorps) and PRDM1 (Montrer PRDM1 Anticorps) as putative targets of microRNA miR (Montrer MLXIP Anticorps)-125b.
Increased expression of MAP3K11 is associated with esophageal cancer.
During hepatocyte lipotoxicity, activated MLK3 induces the release of CXCL10 (Montrer CXCL10 Anticorps)-bearing vesicles from hepatocytes, which are chemotactic for macrophages.
MLK3 serves as a common upstream kinase of AMPK (Montrer PRKAA1 Anticorps) and JNK (Montrer MAPK8 Anticorps) and functions as a direct upstream kinase for AMPK (Montrer PRKAA1 Anticorps) independent of LKB1 (Montrer STK11 Anticorps)
MLK3 represents a newly recognized integral component of HER2 (Montrer ERBB2 Anticorps) biology in HER2 (Montrer ERBB2 Anticorps)+ breast tumors.
MLK3 is a critical factor controlling the activity of kinase networks that control the cellular responses to different concentrations of reactive oxygen species.
In lipotoxic hepatocytes, MLK3 (Montrer KCNK7 Anticorps) activates a MAPK (Montrer MAPK1 Anticorps) signaling cascade, resulting in the activating phosphorylation of STAT1 (Montrer STAT1 Anticorps), and CXCL10 (Montrer CXCL10 Anticorps) transcriptional upregulation.
MAP3K11 might function as an important tumor suppressor neutralized by oncomiR-125b in B-cell leukemia.
During hepatocyte lipotoxicity, activated MLK3 (Montrer KCNK7 Anticorps) induces the release of CXCL10 (Montrer CXCL10 Anticorps)-bearing vesicles from hepatocytes, which are chemotactic for macrophages.
TRB3 (Montrer TRIB3 Anticorps)(-/-) islets show a decrease in both the amplitude and duration of cytokine-stimulated MLK3 (Montrer KCNK7 Anticorps) induction and JNK (Montrer MAPK8 Anticorps) activation.
MLK3 (Montrer KCNK7 Anticorps) limits RhoA (Montrer RHOA Anticorps) activation and injury-induced neointima formation by binding to and inhibiting the activation of p63Rho guanine nucleotide exchange factor (Montrer ARHGEF12 Anticorps), a RhoA (Montrer RHOA Anticorps) activator.
Genetic or pharmacologic inhibition of MLK3 (Montrer KCNK7 Anticorps) blocks fMLP (Montrer FPR1 Anticorps)-mediated motility of neutrophils both in vitro and in vivo, suggesting that MLK3 (Montrer KCNK7 Anticorps) may be a therapeutic target in human diseases characterized by exuberant neutrophil migration.
Data indicate URMC-099 as an orally bioavailable, potent mixed lineage kinase 3 MLK3 inhibitor.
Data from knockout mice suggest that MLK3 (Montrer KCNK7 Anticorps) plays role in saturated fatty acid-induced activation of MAP kinase (Montrer MAPK1 Anticorps) signaling; MLK3 (Montrer KCNK7 Anticorps) appears to be involved in pathogenesis of obesity, adipose tissue in fl ammation, insulin (Montrer INS Anticorps) resistance, and fatty liver disease.
Lysine 63-linked ubiquitination modulates mixed lineage kinase-3 interaction with JIP1 (Montrer MAPK8IP1 Anticorps) scaffold protein (Montrer HOMER1 Anticorps) in cytokine-induced pancreatic beta cell death
These results reveal a novel role for MLK3 (Montrer KCNK7 Anticorps) signaling in the regulation of intestinal epithelial migration in vivo and suggest that MLK3 (Montrer KCNK7 Anticorps) may be an important target for the regulation of intestinal mucosal healing.
The protein encoded by this gene is a member of the serine/threonine kinase family. This kinase contains a SH3 domain and a leucine zipper-basic motif. This kinase preferentially activates MAPK8/JNK kinase, and functions as a positive regulator of JNK signaling pathway. This kinase can directly phosphorylate, and activates IkappaB kinase alpha and beta, and is found to be involved in the transcription activity of NF-kappaB mediated by Rho family GTPases and CDC42.
SH3 domain-containing proline-rich kinase
, mixed lineage kinase 3
, protein-tyrosine kinase PTK1
, src-homology 3 domain-containing proline-rich kinase
, mitogen activated protein kinase kinase kinase 11